In a phase III randomized control trial with 1981 NSCLC patients, PD-1 inhibitors worked more efficaciously in patients with a smoking history while nonsmoking patients showed no survival benefit [121]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.